The purpose of this study is to determine if diflunisal can prevent progressive lower leg
nerve damage in patients with familial amyloidosis polyneuropathy.
Funding Source - FDA Office of Orphan Products Development (OOPD); National Institute of
Neurological Disorders and Stroke (NINDS)
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Boston University
Collaborators:
Food and Drug Administration (FDA) National Institute of Neurological Disorders and Stroke (NINDS)